Interview with Melissa Thomas, Managing Director, Nycomed UK Ltd.
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
Address: Takeda House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Bucks, HP10 0HH
United Kingdom
Tel: +44 (0) 1628 537 900
Web: http://www.takeda.co.uk/uk/
Nycomed is a privately owned, global, market-driven pharmaceutical company with a differentiated portfolio of branded medicines in gastroenterology, respiratory, inflammatory diseases, pain, and osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. With turnover of €3.2 billion in 2009, Nycomed is among the 25 largest pharmaceutical companies in the world and the 15th largest provider of over-the-counter medicines.
In the UK, recent years have seen a dramatic shift in the prescribing landscape. Nycomed UK recognises the need to respond to these significant changes and is committed to adapting its business model to allow it to effectively manage customers’ evolving needs. To this end Nycomed UK has recently introduced a revised model that it believes will allow it to flex and adapt to not only the whole system changes laid out in the recently published White Paper, but also the geographical differences that exist within the NHS. The new structure will provide the platform for national strategies to be implemented through the optimisation of regional opportunities by tailoring the amount and type of resource utilised at a local level as appropriate.
Nycomed markets hospital products throughout Europe and general practitioner and over-the-counter medicines in selected European countries.
Protium> Gastroenterology> Pantoprazole
TachoSil> Tissue Management> 5.5mg fibrinogen/2.0IU thrombin/cm2
Alvesco> Respiratory> Ciclesonide
Preotact> Osteoporosisç> Parathyroid Hormone
Matrifen> Pain Management> Transdermal fentanyl patch
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
See our Cookie Privacy Policy Here
